Overview
You can access the company’s website by clicking here.
News
-
04 Jun 2019 2 min read
Verona Pharma starts Phase II of MDI-delivered ensifentrine in COPD
Verona Pharma starts Phase II of MDI-delivered ensifentrine in COPD Verona Pharma, the dual AIM (VRP) and Nasdaq (VRNA)-listed biotech specialising in respiratory disease, has started a Phase II dose-ranging trial of a metered-dose inhaler (MDI) formulation of its lead product ensifentrine in moderate-to-severe chronic obstructive pulmonary disease (COPD). The trial is randomised, double-blind and […]
-
03 Aug 2018 2 min read
Arix remains highly geared to Autolus value
Arix remains highly geared to Autolus value Arix Bioscience’s 8% investment in Autolus Therapeutics (Nasdaq: AUTL), the recently floated second-generation CAR-T company, now accounts for more than half of the value of its investments, some 25% of its NAV and almost 30% of its stockmarket value, according to calculations by Marten & Co. Arix is by far […]
